癌癥腫瘤康復-廣東愛硒健康管理有限公司官網第27屆歐洲血液學年會（EHA）將于2022年6月9日~12日以線上+線下的形式召開，會議由歐洲血液學會主辦。作為歐洲血液學領域規模最大的國際會議，每年都有來自全球100多個國家的10000余名專業人士與會，一起分享并探討有關血液學的創新理念及最新的科學和臨床研究成果。
隨著中國臨床研究的快速發展，中國在世界血液學領域也發揮著日益重要的作用，在新冠疫情大背景下，更是為世界血液科醫生提供了寶貴的患者管理經驗。今年，中國專家有69篇Poster以及55篇ePoster入圍EHA年會，讓我們一起盤點一下吧。
題目：THERAPEUTIC EFFECT OF TARGETING CASEIN KINASE II / WDR5 AXIS IN T-CELL ACUTE LYMPHOBLASTIC LEUKEMIA
報告人：葛崢
單位：東南大學附屬中大醫院
題目：CLONAL ARCHITECTURE DISSECTING AT SINGLE-CELL RESOLUTION REVEALS MECHANISMS OF CHEMOTHERAPY RESISTANCE AND RELAPSE IN T CELL ACUTE LYMPHOBLASTIC LEUKEMIA
報告人：Jingliao Zhang
單位：中國醫學科學院血液病醫院
題目：COMPREHENSIVE DIAGNOSTICS OF ACUTE LYMPHOBLASTIC LEUKEMIA BY WHOLE TRANSCRIPTOME RNA SEQUENCING
報告人：Jing Li
題目：EARLY RESULTS OF A SAFETY AND EFFICACY STUDY OF ALLOGENEIC TRUUCAR? GC502 IN PATIENTS WITH RELAPSED/REFRACTORY B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA (R/R B-ALL)
報告人：黎詩琦
單位：解放軍聯勤保障部隊902醫院
題目：THE PROGNOSIS FACTORS OF CAR-T THERAPY IN PATIENTS WITH RELAPSED/REFRACTORY B-ALL
報告人：胡星星
單位：陜西省人民醫院
題目：SYNERGISTIC EFFECT OF EZH2 INHIBITOR WITH BCL2 INHIBITOR BY ENHANCING PIK3IP1 EXPRESSION IN ACUTE MYELOID LEUKEMIA
報告人：葛崢
單位：東南大學附屬中大醫院
題目：SYNERGISTIC EFFECT OF A NOVEL COMBINATION OF HDACI CHIDAMIDE WITH CLADRIBINE ON CELL PROLIFERATION ARREST AND APOPTOSIS IN ACUTE MYELOID LEUKEMIA BY TARGETING MYC/HDAC2 SIGNALING
報告人：葛崢
單位：東南大學附屬中大醫院
題目：CHEMORESISTANCE IN ACUTE MYELOID LEUKEMIA: A SINGLE-CELL RNA SEQUENCING APPROACH
報告人：Chieh-Lin Teng
單位：臺中榮民總醫院
題目：CD9 MARKS DIFFERENTIATION AND ANTI-TUMOR IMMUNITY IN PEDIATRIC ACUTE MYELOID LEUKEMIA
報告人：Yaqun Xu
單位：香港中文大學
題目：THZ1, A COVALENT CDK7 INHIBITOR, INDUCES APOPTOSIS IN ACUTE MYELOID LEUKEMIA CELLS AND EXERTS SYNERGISTIC ANTILEUKEMIA ACTIVITY WITH AZACITIDINE
報告人：張帥
單位：北京醫院
題目：ADULT LANGERHANS CELL HISTIOCYTOSIS WITH THYROID GLAND INVOLVEMENT: CLINICAL PRESENTATION, GENOMIC ANALYSIS AND OUTCOME
報告人：蔡華聰
單位：北京協和醫院
題目：SINGLE-CENTER PHASE 2 STUDY OF PD-1 INHIBITOR COMBINED WITH DNA DEMETHYLATION AGENT + CAG REGIMEN IN PATIENTS WITH HIGH-RISK ACUTE MYELOID LEUKEMIA: INTERIM ANALYSIS
報告人：高曉寧
單位：中國人民解放軍總醫院第五醫學中心
題目：ANALYSIS OF THE CLINICAL SIGNIFICANCE AND PROGNOSTIC IMPACT OF TET2 SINGLE NUCLEOTIDE POLYMORPHISM I1762V IN PATIENTS WITH ACUTE MYELOID LEUKEMIA
報告人：呂曉東
單位：河南省腫瘤醫院
題目：ANALYSIS OF GENE MUTATION SPECTRUM AND CORRELATION BETWEEN GENETIC ABNORMALITIES IN 207 PATIANTS WITH T(8; 21) AML
報告人：anbo Nie
題目：IMPROVED OUTCOME OF RELAPSED/REFRACTORY ACUTE MYELOID LEUKEMIA BY ADDITION OF LIPOSOMAL ADRIAMYCIN TO CLAG CHEMOTHERAPY
報告人：姚浛
單位：陸軍軍醫大學第二附屬醫院（新橋醫院）
題目：PRELIMINARY RESULTS OF A PHASE I STUDY OF CLIFUTINIB, A HIGHLY SELECTIVE, POTENT ORAL FLT-3 INHIBITOR, IN PATINETS WITH FLT3-MUTATED RELAPSED OR REFRACTORY ACUTE MYELOID LEUKEMIA
報告人：金潔
單位：浙江大學附屬第一醫院
題目：SYNERGISTIC ACTIVITY OF FTO INHIBITOR FB23-2 WITH IBRUTINIB IN XENOGRAFT MURINE MODEL OF CHRONIC LYMPHOCYTIC LEUKEMIA
報告人：Xinting Hu
單位：山東省立醫院
題目：PHASE 1 STUDY OF LP-108, A SELECTIVE BCL-2 INHIBITOR, IN PATIENTS WITH RELAPSED OR REFRACTORY B-CELL NON-HODGKIN LYMPHOMA
報告人：徐衛
單位：江蘇省人民醫院
題目：CLINICAL STUDY ON THE RELATIONSHIP BETWEEN NON-ABL1 KINASE REGION MUTATION AND TKI DRUG RESISTANCE AND DISEASE PROGRESSION IN CHRONIC MYELOID LEUKEMIA
報告人：呂曉東
單位：河南省腫瘤醫院
題目：PREDICTIVE SCORING SYSTEMS FOR MOLECULAR RESPONSES IN PERSONS WITH CHRONIC MYELOID LEUKEMIA RECEIVING INITIAL IMATINIB THERAPY
報告人：張小帥
單位：北京大學人民醫院
題目：IS THE SECOND-GENERATION TYROSINE KINASE INHIBITOR A BETTER THERAPY THAN IMATINIB FOR PERSONS WITH CHRONIC MYELOID LEUKEMIA PRESENTING IN ACCELERATED-PHASE?
報告人：張小帥
單位：北京大學人民醫院
題目：DHX9 HELICASE DYSFUNCTION CONTRIBUTES TO DISEASE PROGRESSION IN PATIENTS WITH MYELODYSPLASTIC SYNDROMES
報告人：許峰
單位：上海市第六人民醫院
題目：BCOR MUTATION REGULATES MYELODYSPLASTIC SYNDROMES PROGRESSION THROUGH REPRESSING AUTOPHAGY FLUX MEDIATED BY HDAC6 ACTIVATION
報告人：吳凌云
單位：上海市第六人民醫院
題目：DYSFUNCTIONAL BONE MARROW ENDOTHELIAL PROGENITOR CELLS ARE INVOLVED IN PATIENTS WITH MYELODYSPLASTIC SYNDROMES
報告人：Tong Xing
單位：北京大學人民醫院
題目：THE ELEVATION OF RED BLOOD CELL DISTRIBUTION IS AN INDEPENDENT PROGNOSTIC FACTOR FOR JUVENILE MYELOMONOCYTIC LEUKEMIA
報告人：Weiru Liang
單位：中國醫學科學院北京協和醫學院
題目：A SINGLE CENTER HISTORICAL CONTROL STUDY OF ELTROMBOPAG ADDED TO IMMUNOSUPPRESSIVE THERAPY FOR SEVERE APLASTIC ANEMIA IN CHILDREN
報告人：Bixi Yang
單位：首都醫科大學附屬北京兒童醫院
題目：OVEREXPRESSION OF PFKFB4 PROMOTES ADAPTATION TO HYPOXIC MICROENVIRONMENT IN MULTIPLE MYELOMA
報告人：Jie Yang
單位：東南大學附屬中大醫院
題目：DARATUMUMAB, BORTEZOMIB, AND DEXAMETHASONE (D-VD) VERSUS BORTEZOMIB AND DEXAMETHASONE (VD) ALONE IN CHINESE PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA (RRMM): UPDATED ANALYSIS OF LEPUS
報告人：傅衛軍
單位：上海長征醫院
題目：DEVELOPMENT AND VALIDATION OF A FRAILTY PREDICTION MODEL MORE SUITABLE FOR MULTIPLE MYELOMA IN CHINESE PATIENTS: THE TM FRAILTY SCORE.
報告人：李娟
單位：中山大學附屬第一醫院
題目：DOES MINIMAL RESIDUAL DISEASE OF STEM CELL COLLECTION HAVE PROGNOSTIC IMPACT ON PATIENTS WITH MULTIPLE MYELOMA?
報告人：Xu Jingyu
單位：中國醫學科學院血液病醫院
題目：PHASE I STUDY OF TQB3602 CAPSULE, AN ORAL PROTEASOME INHIBITOR, IN RELAPSED/REFRACTORY MULTIPLE MYELOMA
報告人：牛挺
單位：四川大學華西醫院
題目：THE CLINICAL CHARACTERISTICS AND PROGNOSIS OF PATIENTS WITH PRIMARY PLASMA CELL LEUKEMIA (PPCL) UNDER THE NEW IWMG DEFINITION CRITERIA
報告人：唐文嬌
單位：中國醫學科學院血液病醫院
題目：BENDAMUSTINE-POMALIDOMIDE-DEXAMETHASONE (BPD) FOR RELAPSED AND/OR REFRACTOR MULTIPLE MYELOMA WITH EXTRAMEDULLARY DISEASE
報告人：鐘玉萍
單位：青島市市立醫院
題目：EFFECT AND MOLECULAR MECHANISM OF TQ05105, A NOVEL SMALL MOLECULE INHIBITOR OF JAK2 IN MYELOPROLIFERATIVE NEOPLASM
報告人：Wenjun Zhang
單位：中國醫學科學院血液病醫院
題目：PHASE 2 STUDY OF ORAL THALIDOMIDE-CYCLOPHOSPHAMIDE-DEXAMETHASONE FOR RECURRENT/REFRACTORY ADULT LANGERHANS CELL HISTIOCYTOSIS
報告人：Ji-nuo Wang
單位：北京協和醫院
題目：NATURAL HISTORY OF JUVENILE MYELOMONOCYTIC LEUKEMIA
報告人：Wenyu Yang
單位：中國醫學科學院血液病醫院
題目：CLINICAL APPLICABILITY OF TARGETED NEXT-GENERATION SEQUENCING FOR PRECISION MEDICINE IN DIFFUSE LARGE B CELL LYMPHOMA
報告人：黃德鴻
單位：重慶大學附屬腫瘤醫院
題目：ASIA SUBPOPULATION ANALYSIS FROM THE PHASE III POLARIX TRIAL
報告人：宋玉琴
單位：北京大學腫瘤醫院
題目：MACHINE-LEARNING ALGORITHM TO DETECTION OF LYMPHOMA WITH BONE MARROW INVOLVEMENT VIA FDG-18 PET/CT
報告人：Cho-Hao Lee
單位：三軍總醫院
題目：ZANUBRUTINIB PLUS RCHOP(ZR-CHOP) REGIMEN ACHIEVES HIGH COMPLETE RESPONSE RATE IN THE TREATMENT OF NEWLY-DIAGNOSED DOUBLE-EXPRESSION DIFFUSE LARGE B CELL LYMPHOMA
報告人：李增軍
單位：山東省腫瘤醫院
題目：PROGNOSTIC ROLE OF TUMOR P53 MUTATION IN DIFFUSE LARGE B CELL LYMPHOMA: A SYSTEMATIC REVIEW AND META-ANALYSIS
報告人：馬驥
單位：山東省腫瘤醫院
題目：GASTROINTESTINAL BLEEDING SIGNIFICANTLY REDUCED THE EFFICACY AND SURVIVAL OF CD19 CAR-T CELL THERAPY IN PATIENTS WITH GASTROINTESTINAL TRACT INVOLVEMENT OF REFRACTORY/RELAPSED B-CELL LYMPHOMA
報告人：胡凱
單位：北京高博博仁醫院
題目：ZANUBRUTINIB PLUS R-CHOP(RI-CHOP) AS THE TREATMENT FOR DOUBLE EXPRESSION OF MYC/BCL2 IN PATIENTS WITH DIFFUSED LARGE B-CELL LYMPHOMA
報告人：任柯星
單位：四川大學華西醫院
題目：FIRST-IN-HUMAN STUDY OF CD19/BCMA DUAL-TARGETING FAST CAR-T GC012F FOR PATIENTS WITH RELAPSED/REFRACTORY B-CELL NON-HODGKIN’S LYMPHOMA
報告人：陳新鋒
單位：鄭州大學第一附屬醫院
題目：EFFICACY AND TOXICITY FOR CD7 CHIMERIC ANTIGEN RECEPTOR T-CELL THERAPY IN PATIENTS WITH RELAPSED/REFRACTORY T-CELL LYMPHOMA
報告人：胡凱
單位：北京高博博仁醫院
題目：PRELIMINARY RESULTS OF A PHASE Ⅱ STUDY OF ZANUBRUTINIB COMBINED WITH IMMUNOCHEMOTHERAPY IN PATIENTS WITH CD79A/CD79B-MUTANT DIFFUSE LARGE B-CELL LYMPHOMA
報告人：姚志華
單位：河南省腫瘤醫院
題目：EFFICACY ANALYSIS OF PEGASPARGASE, GEMCITABINE, OXALIPLATIN, DEXAMETHASONE COMBINED WITH TISLELIZUMAB IN FIRST-LINE TREATMENT OF PLASMA EBV-DNA POSITIVE EXTRANODAL NK/T CELL LYMPHOMA
報告人：朱尊民
單位：河南省人民醫院
題目：ANTI-PD-1-ANTIBODY (TISLELIZUMAB) COMBINED WITH DEACETYLASE INHIBITOR (CHIDAMIDE), LENALIDOMIDE AND ETOPOSIDE FOR THE TREATMENT OF REFRACTORY/RELAPSED EXTRANODAL NATURAL KILLER/T CELL LYMPHOMA, NASAL
報告人：張蕾
單位：鄭州大學第一附屬醫院
題目：THE INCIDENCE AND SURVIVAL OUTCOMES OF PATIENTS WITH PRIMARY GASTRIC T-CELL LYMPHOMA: A SEER POPULATION-BASED STUDY
報告人：張旻玥
單位：上海交通大學醫學院附屬仁濟醫院
題目：ZANUBRUTINIB AND RITUXIMAB REGIMEN COMBINED WITH INTRAVITREAL METHOTREXATE FOLLOWED BY ZANUBRUTINIB MAINTENANCE FOR TREAT-NAIVE PRIMARY VITREORETINAL LYMPHOMA: A PROSPECTIVE PHASE II STUDY
報告人：張炎
單位：北京協和醫院
題目：GRANULOCYTE COLONY-STIMULATING FACTOR MOBILIZATION FACILITATES ANTI-GRAFT-VERSUS-HOST DISEASE AND GRAFT-VERSUS-LEUKEMIA EFFECTS OF MUCOSA-ASSOCIATED INVARIANT T CELLS THROUGH DISTINCT FUNCTIONAL SUBSE
報告人：高夢鴿
單位：北京大學人民醫院
題目：A REVIEW OF HEMATOPOIETIC CELL TRANSPLANTATION IN TAIWAN: DATA AND TRENDS DURING 2009–2018
報告人：Yu-Hung Wang
單位：國立臺灣大學醫學院附設醫院
題目：HIGHER DOSE OF CD34+ CELLS PROMOTES EARLY RECONSTITUTION OF NATURAL KILLER CELLS AND IS ASSOCIATED WITH BETTER OUTCOMES AFTER UNMANIPULATED HEMATOPOIETIC STEM CELL TRANSPLANTATION FOR MYELOID MALIGNAN
報告人：Fei Zhao
單位：中國醫學科學院血液病醫院
題目：DIFFERENT DOSES OF ANTITHYMOCYTE GLOBULIN (ATG) AS PART OF THE PREPARATIVE REGIMEN INHEMATOPOIETIC STEM CELL TRANSPLANTATION (HSCT)
報告人：熊敏
單位：北京陸道培醫院
題目：HLA MISMATCHED UNRELATED STEM CELL TRANSPLANTATION USING ANTITHYMOCYTE GLOBULIN IS A SUITABLE ALTERNATIVE FOR PATIENTS LACKING HLA-MATCHED UNRELATED DONORS: SINGLE CENTER LONG-TERM FOLLOW-UP DATA ANAL
報告人：高蕾
單位：陸軍軍醫大學第二附屬醫院（新橋醫院）
題目：EFFECTS OF CLONAL HEMATOPOIESIS OF INDETERMINATE POTENTIAL FROM HEALTHY DONORS ON RECIPIENTS AFTER TRANSPLANTATION AND RELATED RESEARCH
報告人：Biao Shen
單位：中國醫學科學院血液病醫院
題目：THE GUIDING SIGNIFICANCE OF IMMUNE CELL SUBSET MONITORING IN IMMUNE RECONSTITUTION IN PATIENTS WITH CAR-T BRIDGED ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION
報告人：趙瑋
單位：北京陸道培醫院
題目：MACHINE LEARNING ALGORITHM AS A PROGNOSTIC TOOL FOR VENOUS THROMBOEMBOLISM IN ALLOGENIC TRANSPLANT PATIENTS
報告人：鄧睿歆
單位：北京大學人民醫院
題目：IN VIVO G-CSF TREATMENT ACTIVATES THE GR-SOCS1 AXIS TO SUPPRESS IFN-Γ SECRETION BY NATURAL KILLER CELLS
報告人：Xunhong Cao
單位：北京大學人民醫院
題目：BTK INHIBITORS IMPROVE CART19 CELL THERAPY BY MODULATING IMMUNE SYSTEM
報告人：梅恒
單位：華中科技大學同濟醫學院附屬協和醫院
題目：SINGLE-CELL TRANSCRIPTOMIC CHARACTERIZATIONS OF BONE MARROW MONONUCLEAR CELLS AND CAR-T PRODUCTS ASSOCIATED WITH EFFICACY AND TOXICITY IN B-ALL PATIENTS
報告人：梅恒
單位：華中科技大學同濟醫學院附屬協和醫院
題目：EFFICACY OF RECOMBINANT HUMANTHROMBOPOIETIN ON CHILDREN IMMUNE THROMBOCYTOPENIA AND ITS INFLUENCING FACTORS
報告人：馬靜瑤
單位：首都醫科大學附屬北京兒童醫院
題目：METABOLIC ABNORMALITY AND GLUCOCORTICOID RECEPTOR MODULATION OF MYELOID-DERIVED SUPPRESSOR CELLS IN IMMUNE THROMBOCYTOPENIA PATIENTS AND AN ACTIVE MURINE MODEL
報告人：Shuwen Wang
單位：山東大學
題目：HDAC3 RS2530223 IS ASSOCIATED WITH INCREASED SUSCEPTIBILITY AND SEVERITY OF PRIMARY IMMUNE THROMBOCYTOPENIA
報告人：Shuwen Wang
單位：山東大學
題目：MACHINE-LEARNING-BASED MORTALITY PREDICTION OF ICH IN ADULTS WITH ITP: A NATIONWIDE REPRESENTATIVE MULTICENTRE STUDY
報告人：Shan Chong
單位：北京大學人民醫院
題目：CLINICAL EFFICACY AND SAFETY OF SWITCHING ELTROMBOPAG AND RH-TPO IN PATIENTS WITH IMMUNE THROMBOCYTOPENIA DURING THE COVID-19 PANDEMIC
報告人：Xuan Cai
單位：北京大學人民醫院
題目：COMPLEMENT ACTIVATION REGULATES PLATELET HOMEOSTASIS BY ARRESTING THE ANTI-INFLAMMATORY EFFECTS OF INTERLEUKIN-35 IN IMMUNE THROMBOCYTOPENIA
報告人：Yejun Wu
單位：北京大學血液研究所
題目：PERSONALIZED MACHINE-LEARNING-BASED PREDICTION FOR CRITICAL IMMUNE THROMBOCYTOPENIA BLEEDS: A NATIONWIDE DATA STUDY
報告人：Zhuo-Yu An
單位：北京大學人民醫院
題目：OPTIMIZED PROPHYLAXIS BASED ON INDIVIDUALIZED TARGET TROUGH FVIII LEVEL IN PEDIATRIC PATIENTS WITH SEVERE HEMOPHILIA A
報告人：Kun Huang
單位：首都醫科大學附屬北京兒童醫院
題目：DONOR-DERIVED CD19 CAR-T CELLS AND CHEMOTHERAPY PLUS DONOR LYMPHOCYTE INFUSION IN THE TREATMENT OF RECURRENT CD19+ B-ALL AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION
報告人：張曦
單位：陸軍軍醫大學第二附屬醫院（新橋醫院）
題目：GENETIC CHARACTERISTICS AND CD7-CAR-T THERAPY OF TRAD::MYC TRANSLOCATION POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA PATIENTS
報告人：劉紅星
單位：河北燕達陸道培醫院
題目：NKG2D-MEDIATED ANTI-TUMOR IMMUNITY CONTRIBUTES TO THE FAVORABLE PROGNOSIS IN APL
報告人：王懷宇
單位：西安交通大學第一附屬醫院
題目：GILTERITINIB VERSUS SALVAGE CHEMOTHERAPY FOR RELAPSED/REFRACTORY FLT3-MUTATED ACUTE MYELOID LEUKEMIA: A PHASE 3, RANDOMIZED, MULTICENTER, OPEN-LABEL TRIAL IN ASIA
報告人：王建祥
單位：中國醫學科學研血液病醫院（天津血研所）
題目：SINGLE-CELL RNA SEQUENCING REVEALS THE HETEROGENEITY OF TUMOR CELLS AND IMMUNE MICROENVIRONMENT IN RICHTER SYNDROME AND ACCELERATED CLL
報告人：Yeqin Sha
單位：南京醫科大學第一附屬醫院
題目：DOWN-REGULATION OF RING1 AND YY1 BINDING (RYBP) LEADS TO EPIGENETIC OVEREXPRESSION OF ANTI-APOPTOTIC PROTEIN BCL2 IN MYELODYSPLASTIC SYNDROMES
報告人：許峰
單位：上海市第六人民醫院
題目：PROGNOSTIC SIGNIFICANCE OF SERIAL CIRCULATING TUMOR DNA STATUS POST TREATMENT IN MYELODYSPLASTIC SYNDROMES AND ACUTE MYELOID LEUKEMIA
報告人：佟紅艷
單位：浙江大學附屬第一醫院
題目：CORRELATION ANALYSIS OF DNA METHYLATION LEVEL AND CLINICAL CHARACTERISTICS IN JMML PATIENTS
報告人：Yuli Cai
單位：中國醫學科學院血液病醫院
題目：COMBINATION THERAPY OF ELTROMBOPAG AND CYCLOSPORINE A CAN IMPROVE HEMATOPOIESIS IN PATIENTS WITH LOWER RISK MYELODYSPLASTIC SYNDROME
報告人：Luxi Song
單位：上海市第六人民醫院
題目：ANTI-PD-1 ANTIBODY (SINTILIMAB) PLUS DECITABINE AS FIRST LINE TREATMENT FOR PATIENTS WITH HIGHER-RISK MYELODYSPLASTIC SYNDROME（MDS）: PRELIMINARY RESULTS FROM A SINGLE-ARM, OPEN-LABEL, PHASE II STUDY
報告人：Jing Wang
單位：北京大學人民醫院
題目：ANALYSIS OF THE CLINICAL FEATURES, PROGNOSIS AND GENE MUTATIONS IN PRIMARY MYELODYSPLASTIC SYNDROME PATIENTS WITH MYELOFIBROSIS
報告人：Gaixiang Xu
單位：浙江大學附屬第一醫院
題目：THE EXPRESSION LEVEL OF WT1 MRNA IN PATIENTS WITH IDIOPATHIC CYTOPENIA OF UNDETERMINED SIGNIFICANCE (ICUS) PROGRESSING TO MYELODYSPLASTIC SYNDROME (MDS)
報告人：Xingnong Ye
單位：浙江大學附屬第一醫院
題目：ENRICHED CD16+ MONOCYTES DRIVE T LYMPHOCYTES CELL RESPONSES IN APLASTIC ANEMIA
報告人：Meili Ge
單位：中國醫學科學院血液病醫院
題目：PREDICTING RESPONSE TO RABBIT ATG-BASED INTENSIVE IMMUNOSUPPRESSIVE THERAPY COMBINED WITH ELTROMBOPAG IN CHINESE ADULT PATIENTS WITH SEVERE APLASTIC ANEMIA
報告人：何廣勝
單位：南京醫科大學第一附屬醫院
題目：THE INCIDENCE, OUTCOMES, AND RISK FACTORS OF SECONDARY POOR GRAFT FUNCTION IN HAPLOIDENTICAL HEMATOPOIETIC STEM CELL TRANSPLANTATION FOR ACQUIRED APLASTIC ANEMIA
報告人：Fan Lin
單位：北京大學血液病研究所
題目：HIGH MUTATIONAL BURDEN OF CHROMATIN MODIFYING GENES DEFINES A RELATIVELY INDOLENT SUBGROUP OF PLASMA CELL DYSCRASIAS
報告人：Xuezhu Wang
單位：北京協和醫院
題目：IDENTIFICATION OF M7G RNA METHYLATION REGULATORS AND M7G-RELATED GENES IN MULTIPLE MYELOMA
報告人：Manya Yu
單位：山東中醫藥大學
題目：TARGETING CALCINEURIN/NFATC1 SIGNALING SENSITIZES PROTEASOME INHIBITION TREATMENT IN MULTIPLE MYELOMA
報告人：Jinglin Zhang
單位：香港中文大學
題目：DARATUMUMAB PLUS BORTEZOMIB AND DEXAMETHASONE IN NEWLY DIAGNOSED PATIENTS WITH MAYO 2004 STAGE 3 LIGHT-CHAIN AMYLOIDOSIS: A PROSPECTIVE PHASE 2 STUDY
報告人：Ya-juan Gao
單位：北京協和醫院
題目：RENAL RESPONSE OF POMALIDOMIDE WITH BORTEZOMIB AND DEXAMETHASONE IN NEWLY DIAGNOSED MULTIPLE MYELOMA PATIENTS WITH RENAL IMPAIRMENT
報告人：高文
單位：首都醫科大學附屬北京朝陽醫院
題目：EFFECTIVENESS AND SAFETY OF SELINEXOR-BASED REGIMEN IN THE TREATMENT OF RELAPSED AND REFRACTORY MULTIPLE MYELOMA: A MULTICENTER REAL-WORLD STUDY FROM CHINA
報告人：李娟
單位：中山大學第一附屬醫院
題目：CLINICAL CHARACTERISTICS, SURVIVAL OUTCOMES AND PROGNOSIS IN 123IMMUNOGLOBULIN D MULTIPLE MYELOMA PATIENTS: A RETROSPECTIVE SINGLE-CENTER
報告人：Jiahui Liu
單位：中國醫學科學院血液病醫院
題目：A PHASE I STUDY OF C-CAR088, A NOVEL HUMANIZED ANTI-BCMA CAR T CELL THERAPY IN RELAPSED/REFRACTORY MULTIPLE MYELOMA
報告人：Xiaoyan Qu
單位：南京醫科大學第一附屬醫院
題目：COMPARISON OF VENOUS THROMBOEMBOLISM INCIDENCE IN MULTIPLE MYELOMA PATIENTS RECEIVING LENALIDOMIDE-BASED REGIMENS WITH RIVAROXABAN OR ASPIRIN THROMBOPROPHYLAXIS
報告人：Siyuan Cui
單位：山東中醫藥大學附屬醫院
題目：SAFETY AND EFFICACY OF BCMA-CAR-T IMMUNE CELLS DERIVED FROM CORD BLOOD IN THE TREATMENT OF RELAPSED AND REFRACTORY MULTIPLE MYELOMA
報告人：Ying Gao
單位：陜西省人民醫院
題目：REAL-WORLD SAFETY OF RUXOLITINIB IN PATIENTS WITH INTERMEDIATE OR HIGH RISK OF PRIMARY MYELOFIBROSIS, POST-POLYCYTHEMIA VERA MYELOFIBROSIS OR POST-ESSENTIAL THROMBOCYTHEMIA MYELOFIBROSIS IN CHINA
報告人：肖志堅
單位：中國醫學科學院血液病醫院
題目：CAMRELIZUMAB (CAM) COMBINED WITH GEMOX CHEMOTHERAPY RESULTS IN HIGH COMPLETE METABOLIC RESPONSE RATES IN RELAPSED/REFRACTORY CLASSIC HODGKIN LYMPHOMA (CHL): A PHASE II TRIAL
報告人：Yan Xie
單位：北京大學腫瘤醫院
題目：PRELIMINARY RESULTS OF A PHASE 1 STUDY OF NOVEL BCL-2 INHIBITOR LISAFTOCLAX (APG-2575) IN CHINESE PATIENTS (PTS) WITH RELAPSED OR REFRACTORY (R/R) NON-HODGKIN LYMPHOMAS (NHLS)
報告人：Mingyuan Sun
單位：中國醫學科學院血液病醫院
題目：PROGNOSTIC SIGNIFICANCE OF ABSOLUTE MONOCYTE COUNT AND LYMPHOCYTE TO MONOCYTE RATIO IN MUCOSA-ASSOCIATED LYMPHOID TISSUE (MALT) LYMPHOMA
報告人：Yue Li
單位：南京醫科大學第一附屬醫院
題目：THE EFFICACY AND SAFETY OF ZANUBRUTINIB AND DEXAMETHASONE IN SYMPTOMATIC WALDENSTROM MACROGLOBULINNEMIA
報告人：陳文明
單位：首都醫科大學附屬北京朝陽醫院
題目：ANTITUMOR ACTIVITY AND SAFETY OF ZANUBRUTINIB COMBINED WITH R-CHOP REGIMEN IN THE TREATMENT OF NEWLY DIAGNOSED NON-GCB DLBCL WITH EXTRANODAL INVOLVEMENT: A PROSPECTIVE PHASE II STUDY.
報告人：C. Li
單位：蘇州大學第一附屬醫院
題目：ZANUBRUTINIB, LENALIDOMIDE PLUS R-CHOP (ZR2-CHOP) AS THE FIRST-LINE TREATMENT FOR NON-GCB DIFFUSED LARGE B-CELL LYMPHOMA (DLBCL)
報告人：朱華淵
單位：南京醫科大學第一附屬醫院
題目：PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA: A RETROSPECTIVE STUDY OF THE ZRMA REGIMEN（ZANUBRUTINIB, RITUXIMAB, METHOTREXATE AND CYTARABINE）
報告人：Youhong Tang
單位：中南大學湘雅醫院
題目：REAL-WORLD EXPERIENCE OF OUTCOMES WITH GLOFITAMAB SALVAGE THERAPY FOR RELAPSE/REFRACTORY B-CELL LYMPHOMA IN TAIWAN: MINIMAL SAFETY CONCERN WITH HEPATITIS B REACTIVATION
報告人：Shang-Ju Wu
單位：國立臺灣大學醫學院副設醫院
題目：GENOTYPING ON CIRCULATING TUMOR DNA IMPROVES MUTATION DETECTION RATE IN HIGH-RISK DIFFUSE LARGE B-CELL LYMPHOMA
報告人：徐衛
單位：南京醫科大學第一附屬醫院
題目：RUXOLITINIB COMBINED WITH DEXAMETHASONE IN ADULT PATIENTS WITH NEWLY DIAGNOSED HEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS: INTERIM ANALYSIS OF A PROSPECTIVE, SINGLE-CENTER, SINGLE-ARM, PHASE 2 CLINICAL TRIAL
報告人：De Zhou
單位：浙江大學附屬第一醫院
題目：TARGETED INHIBITION OF DHODH IS SYNERGISTIC WITH BCL2 BLOCKADE IN LYMPHOMA WITH CONCURRENT MYC AND BCL2 REARRANGEMENT
報告人：閆曉菁
單位：中國醫科大學第一附屬醫院
題目：HSA_CIRC_0001599 REGULATES IL18 LEVELS IN AGVHD VIA CERNA MECHANISM
報告人：Mengting Xia
單位：山東中醫藥大學
題目：ENGRAFTMENT AND MOBILIZATION OF HUMAN HEMATOPOIETIC STEM/PROGENITOR CELLS ALIGNS WITH DYNAMIC OSCILLATION OF TETRASPANIN CD9
報告人：Wing Hei Ng
單位：香港中文大學
題目：RUXOLITINIB COMBINED WITH GLUCOCORTICOID IN THE FIRST-LINE TREATMENT OF GRAFT-VERSUS-HOST DISEASE IN CHILDREN: A SINGLE CENTER RETROSPECTIVE STUDY
報告人：Kai Chen
單位：上海市兒童醫院
題目：HAPLO-CORD VS HAPLOIDENTICAL TRANSPLANT IN 49 CHILDREN – A RETROSPECTIVE SINGLE CENTER ANALYSIS
報告人：Pan Fu
單位：上海市兒童醫院
題目：SECOND PRIMARY MALIGNANCY AFTER HEMATOPOIETIC STEM CELL TRANSPLANTATION
報告人：Tran-Der Tan
單位：中國臺灣顧氏基金孫中山癌癥中心
題目：A SINGLE-ARM, PROSPECTIVE MULTICENTER CLINICAL STUDY OF RELATED HLA HAPLOIDENTICAL PERIPHERAL BLOOD HEMATOPOIETIC STEM CELL TRANSPLANTATION WITHOUT IN VITRO T-CELL DEPLETION FOR HEMATOLOGICAL MALIGNAN
報告人：Ming Jiang
單位：新疆醫科大學第一附屬醫院
題目：THE EFFICACY AND SAFETY OF MODIFIED MELPHALAN AND BUSULFAN-BASED REGIMEN FOR ALLOGENEIC TRANSPLANTATION IN REFRACTORY/RELAPSED AML PATIENTS
報告人：Shulian Chen
單位：中國醫學科學院血液病醫院
題目：COMPARISON OF AUTOLOGOUS AND ALLOGENEIC STEM CELL TRANSPLANTATION FOR ADULT PATIENTS WITH PHILADELPHIA CHROMOSOME-NEGATIVE ACUTE LYMPHOBLASTIC LEUKEMIA IN FIRST COMPLETE REMISSION
報告人：Rongli Zhang
單位：中國醫學科學院血液病醫院
題目：THE PRELIMINARY SAFETY AND EFFICACY STUDY OF SC-U02, A NON-VIRAL GENOME TARGETING, ANTI-CD19 UNIVERSAL CAR-T PRODUCT, IN RELAPSED/REFRACTORY (R/R) DIFFUSE LARGE B-CELL LYMPHOMA PATIENTS
報告人：Li Liu
單位：第四軍醫大學唐都醫院
題目：INITIAL SAFETY AND EFFICACY STUDY OF RM-001, AUTOLOGOUS HBG1/2 PROMOTER-MODIFIED CD34+ HEMATOPOIETIC STEM AND PROGENITOR CELLS, IN TRANSFUSION-DEPENDENT ΒETA-THALASSEMIA
報告人：Li Wang
單位：解放軍第923醫院
題目：CLINICAL OBSERVATION OF PATHOGEN MICROBIAL NEXT-GENERATION SEQUENCING ASSISTED IN INFECTION DIAGNOSIS AND TREATMENT OF PATIENTS WITH HEMATOLOGICAL TUMORS
報告人：張曦
單位：陸軍軍醫大學第二附屬醫院(新橋醫院)
題目：DISTRIBUTION AND ANTIBIOTIC RESISTANCE PROFILE OF PATHOGENIC MICROORGANISMS CAUSING NOSOCOMIAL INFECTION IN PATIENTS UNDERGOING HEMATOPOIETIC STEM CELL TRANSPLANTATION
報告人：Yimei Feng
單位：陸軍軍醫大學第二附屬醫院(新橋醫院)
題目：CLINICAL SIGNIFICANCE OF CYTOMEGALOVIRUS DRUG RESISTANCE GENE MUTATIONS IN CYTOMEGALOVIRUS INFECTION AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION
報告人：Jingjing Wen
單位：電子科技大學醫學院附屬綿陽醫院
題目：EFFICACY AND SAFETY OF ELTROMBOPAG IN THE TREATMENT OF CHRONIC HEPATITIS B VIRUS INFECTION PATIENTS WITH THROMBOCYTOPENIA（HBV-TP）: A PROSPECTIVE, MULTI-CENTER, SINGLE ARM, PHASE II TRAIL
報告人：Yunfei Chen
單位：中國醫學科學院血液病醫院
題目：ELTROMBOPAG TREATMENT, OUTCOMES AFTER DISCONTINUATION IN ADULT PATIENTS WITH PRIMARY IMMUNE THROMBOCYTOPENIA, AND EXPLORATION OF POTENTIAL PREDICTIVE FACTORS: A REAL-WORLD CLINICAL EXPERIENCE
報告人：Xiaofan Liu
單位：中國醫學科學院血液病醫院
題目：LONG TERM SAFETY AND EFFICACY OF RECOMBINANT HUMAN COAGULATION FACTOR VIII (SCT800) IN PREVIOUSLY TREATED PATIENTS WITH SEVERE HEMOPHILIA A
報告人：Feng Xue
單位：中國醫學科學院血液病醫院
題目：REGULAR HOSPITAL VISITS IMPROVE THE PROGNOSIS OF MULTIPLE MYELOMA PATIENTS
報告人：Xiaozhe Li
單位：中山大學附屬第一醫院
題目：QUALITY OF LIFE IN CHILDREN WITH BETA-THALASSEMIA MAJOR: A CROSS-SECTIONAL STUDY IN CHINA
報告人：Zhen Song
單位：中國醫學科學院血液病醫院
注：排名不分先后，按照摘要號進行，如有遺漏，請給我們留言~
加硒教授微信：623296388，送食療電子書，任選一本